348133-45-9

Usage

General Description

2H-Benzimidazol-2-one,6-fluoro-1,3-dihydro-1-methyl-(9CI) is a chemical compound with the molecular formula C9H8FN3O. It is a derivative of benzimidazole and contains a fluorine atom and a methyl group. 2H-Benzimidazol-2-one,6-fluoro-1,3-dihydro-1-methyl-(9CI) is a heterocyclic organic molecule with potential pharmaceutical applications due to its structural features. Its synthesis, properties, and biological activities are of interest to researchers in the fields of medicinal chemistry and drug design. Further studies are needed to explore its potential uses and effects in various applications, including drug development and material sciences.

Upstream product

• 32315-10-9 bis(trichloromethyl) carbonate 
• 348133-46-0 5-fluoro-N¹-methylbenzene-1,2-diamine 
• 362670-06-2 (5-fluoro-2-nitrophenyl)carbamic acid tert-butyl ester 
• 2369-11-1 5-fluoro-2-nitroaniline 
• 120381-42-2 4-fluoro-2-methylaminonitrobenzene 
• 446-35-5 2,4-Difluoronitrobenzene 
• 57-13-6 urea 

Downstream Products

• 2050908-30-8 1-(2-chloropyrimidin-4-yl)-5-fluoro-3-methyl-1H-benzo[d]imidazol-2(3H)-one 

Relevant academic research and scientific papers

2, 4-DI-(NITROGEN CONTAINING GROUP) SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF

Provided are a 2, 4-di-(nitrogen containing group) substituted pyrimidine compound represented by a general formula (I), a pharmaceutically acceptable salt and a stereoisomer thereof, a preparation method thereof, and a use thereof in preparation of anti-tumor drugs. The compound having a structural feature shown in the general formula (I) can selectively suppress activity of mutant epidermal growth factor receptors (EGFR), including single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. The compound has a weak suppression effect on wild-type EFGR and a very high selectivity, and thus it has a potential to be used in preparation of drugs for treating EGFR mutant tumors, especially non-small cell lung cancer (NSCLC) comprising a T790M EGFR mutation.

PARG INHIBITORY COMPOUNDS

The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity: wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.

GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain

The BRPF (Bromodomain and PHD Finger-containing) protein family are important scaffolding proteins for assembly of MYST histone acetyltransferase complexes. A selective benzimidazolone BRPF1 inhibitor showing micromolar activity in a cellular target engag

1,3-dimethyl benzimidazolones are potent, selective inhibitors of the brpf1 bromodomain

The BRPF (bromodomain and PHD finger-containing) protein family are important scaffolding proteins for assembly of MYST histone acetyltransferase complexes. Here, we report the discovery, binding mode, and structure-activity relationship (SAR) of the firs

TRICYCLIC COMPOUNDS AS TEC KINASE INHIBITORS

The present invention is directed to tricyclic compounds of formula (I) as Tec kinase inhibitors, in particular ITK (interleukin-2 inducible tyrosine kinase) inhibitors. Also provided herein are processes for preparing compounds described herein, intermed

Substituted piperazine derivatives, the preparation thereofand their use as medicaments

The present invention relates to substituted piperazine derivatives of general formula , (I wherein Ra, Rb, Rc, Rf, Rg, X, m and n are defined as in claim 1, the isomers and salts thereof, particularly the physiologically acceptable salts thereof, which are valuable inhibitors of the microsomal triglyceride-transfer protein (MTP), medicaments containing these compounds and their use, as well as the preparation thereof.